Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ProChon Biotech Ltd.

This article was originally published in Start Up

Executive Summary

Prochon Biotech believes it has found a key receptor regulating bone growth, and hopes to develop new drugs for bone growth disorders, with an initial focus on achondroplasia, the most common form of human dwarfism.

You may also be interested in...

TiGenix NV

Belgian start-up TiGenix NV's cartilage repair treatment ChondroCelect may overcome a key hurdle faced by most existing therapies, by selecting in advance of implantation only those cartilage cells least likely to mineralize.

Promised Land for Biotechnology

Israel is the hottest single country for high-tech start-ups in general, but advocates of life sciences say that additional funding specifically for biotechnology is needed. Without a strong pharmaceutical industry, Israel lacks the infrastructure necessary to nurture start-ups, for example, experienced executives to run companies.

Women's Health: Too early or Too Late?

As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts